Profile image
Story Views

Last Hour:
Last 24 Hours:

Acyl CoA Desaturase Pipeline Review, H2 2016: Therapeutics Analysis by Stage of Development, Drug Target, MoA, RoA & Molecule Type

Thursday, November 3, 2016 4:29
% of readers think this story is Fact. Add your two cents.

Latest Acyl CoA Desaturase Pipeline Review, H2 2016, provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics.

Acyl CoA Desaturase therapeutics industry report provides comprehensive information on the therapeutics under development for Acyl CoA Desaturase, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acyl CoA Desaturase and features dormant and discontinued projects.

Browse more detail information about Acyl CoA Desaturase market report at:

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key players in Acyl CoA Desaturase – Pipeline Review, H2 2016:

  • Daiichi Sankyo Company, Limited
  • Galmed Pharmaceuticals Ltd
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Novartis AG
  • Sanofi
  • Thesan Pharmaceuticals, Inc.
  • Xenon Pharmaceuticals Inc.

Get a PDF Sample of Acyl CoA Desaturase Market Research Report at:

Drug Profiles of Included in Acyl CoA Desaturase Therapeutics Development Market Report

  • GSK-1940029
  • SAR-224
  • Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis
  • Small Molecule to Inhibit SCD1 for Metabolic Disorders
  • XEN-801

And other drug profiles
Have any query? ask our expert @

Key Topics Covered:
2.Acyl CoA Desaturase Overview
3.Acyl CoA Desaturase Therapeutics Development
4.Pipeline Products for Acyl CoA Desaturase – Overview
5.Pipeline Products for Acyl CoA Desaturase – Comparative Analysis
6.Acyl CoA Desaturase – Therapeutics under Development by Companies
7.Acyl CoA Desaturase – Therapeutics under Investigation by Universities/Institutes
8.Acyl CoA Desaturase Products Glance
9.Late Stage Products
10.Clinical Stage Products
11.Early Stage Products
12.Acyl CoA Desaturase – Products under Development by Companies
13.Acyl CoA Desaturase – Products under Investigation by Universities/Institutes
14.Acyl CoA Desaturase – Companies Involved in Therapeutics Development
15.Acyl CoA Desaturase Drug Profiles
16.Acyl CoA Desaturase Dormant Projects
17.Acyl CoA Desaturase Discontinued Products
18.Acyl CoA Desaturase Featured News & Press Releases

Jun 07, 2016: Galmed Pharmaceuticals Expands its Ongoing Phase IIb ARREST Study to China

Jun 01, 2016: Galmed Pharmaceuticals Randomizes 120th Patient in the ARREST Trial

Mar 30, 2016: Aramchol Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease

Mar 01, 2016: Galmed Pharmaceuticals Announces the Enrollment of the First Patient in the ARRIVE Study

Feb 10, 2016: Xenon Initiates Phase 2 Clinical Trial of XEN801 to Treat Moderate to Severe Acne

Dec 01, 2015: Galmed Pharmaceuticals Announces FDA Clearance of IND of Aramachol for the Treatment of Patients with HIV-Associated Lipodystrophy and Nonalcoholic Fatty Liver Disease

Sep 24, 2015: Xenon Pharmaceuticals Announces Initiation of XEN801 Phase 1 Clinical Trial
And Continue…

Get Discount on Acyl CoA Desaturase Market Research Report at:


This 55 pages research study help to:
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acyl CoA Desaturase
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acyl CoA Desaturase pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


About Absolute Report:

Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.


Mr. Ameya Pingaley

Absolute Reports

+1-408 520 9750

Email –

We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.